A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
The group is keeping faith with the novel target KLK2.
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.